AstraZeneca plc vs Tyson Foods, Inc. — how do they compare? AstraZeneca plc trades at $157.61 (market cap $248.14B), while Tyson Foods, Inc. trades at $55.77 (market cap $19.85B). The key difference: AstraZeneca plc is far larger — about 12.5× Tyson Foods, Inc.'s market cap, and Tyson Foods, Inc. pays the higher dividend (3.62%). Which is the better fit depends on your goals.
| AZN | TSN | |
|---|---|---|
Market Cap | $248.14B | $19.85B |
Sector | Health | Consumer Staples |
52-Week High | $209.48 | $68.75 |
52-Week Low | $147.06 | $50.72 |
Enterprise Value | $275.41B | $27.12B |
Dividend Yield | 2.01% | 3.62% |
Signals from Pluang's Aura AI — not financial advice
AstraZeneca (AZN) trades at $157.39, down 2.79% amid bearish technical signals and merger speculation. The company demonstrates strong fundamentals with revenue growth to $58.74B in 2025 and a net income margin of 17.02%. Recent earnings have consistently beaten estimates, and analyst consensus is positive with 47.5% buy ratings. However, news of potential merger talks with Bristol Myers Squibb and a related legal investigation have introduced volatility.
The outlook is mixed; solid profitability and growth support long-term value, but near-term price pressure from technical indicators and merger uncertainty presents a cautious entry point. Key risks include deal execution challenges and integration complexities should a merger proceed.
Tyson Foods (TSN) trades at $57.16, down 1.52% on the day, amid a bearish technical signal. The company reported mixed Q3 2026 earnings, beating EPS estimates but missing revenue expectations, with beef segment losses weighing on results. Analyst consensus is a Buy with a $68.50 price target, but technical indicators show selling pressure. Recent news highlights debt tender offers and a maintained dividend, while cash flow trends show volatility.
The outlook is cautious; strong chicken and prepared foods segments provide stability, but persistent beef losses and volume declines pose near-term risks. Valuation metrics like P/E of 34.83 appear elevated relative to modest profitability, yet the stock trades below analyst targets, suggesting potential upside if operational challenges ease.
Trailing returns across standard periods
Latest headlines on both assets
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, and immunology. The majority of sales come from international markets with the United States representing close to one third of its sales.
Read more on AZN →Tyson Foods is the largest U.S. producer of processed chicken and beef. It's also a large producer of processed pork and protein-based products under the brands Jimmy Dean, Hillshire Farm, Ball Park, Sara Lee, Aidells, State Fair, and Raised & Rooted, to name a few. Tyson sells 81% of its products through various U.S. channels, including retailers (47% in fiscal 2021), food service (32%), and other packaged food and industrial companies (10%). In addition, 11% of the company's revenue comes from exports to Canada, Mexico, Brazil, Europe, China, and Japan.
Read more on TSN →